Molecular Genetic Study of Avascular Necrosis of the Femoral Head

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by National Health Research Institutes, Taiwan.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier:
NCT00260897
First received: December 1, 2005
Last updated: May 7, 2007
Last verified: May 2007
  Purpose

Avascular necrosis of the femoral head (ANFH) is a debilitating disease that commonly leads to destruction of the hip joint in patients at middle age of life and often requires surgical intervention. Previously, we have identified the collagen type II, alpha 1 (COL2A1) gene as the ANFH disease gene. In this grant proposal, we will establish cell ine and animal models to understand the pathophysiology of ANFH, and extend our ongoing study for identifying genes responsible for non-familiar ANFH by looking into other interacting molecules of the pathway.


Condition
Osteonecrosis

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Molecular Genetic Study of Avascular Necrosis of the Femoral Head-Revealing ANFH Pathogenesis Mechanism by Cell and Animal Models

Resource links provided by NLM:


Further study details as provided by National Health Research Institutes, Taiwan:

Estimated Enrollment: 500
Study Start Date: May 2003
Estimated Study Completion Date: April 2008
Detailed Description:

Avascular necrosis of the femoral head (ANFH) is a debilitating disease that usually leads to destruction of the hip joint in the third to fifth decade of life (average age, 36 years). The disease prevalence is unknown, but it has been estimated that 10,000-20,000 new cases per year are diagnosed in the United State. Nearly half of the patients eventually require hip replacement before 40 years of age. The etiology of ANFH is unknown but previous studies indicated that heritable thrombophilia (increased tendency to form thrombi) and hypofibrinolysis (reduced ability to lyse thrombi), alcohol intake, and steroid use are risk factors for ANFH.

Although the majority of idiopathic ANFH cases are sporadic, recently we identified three ANFH families showing autosomal dominant inheritance. By genome-wide scan, a significant two-point LOD score of 3.45 at = 0 was obtained between one ANFH pedigree and marker D12S85 on chromosome 12. High-resolution mapping was conducted in a second ANFH family and replicated the linkage to D12S368. When an age-dependent penetrance model was applied, the combined multipoint LOD score achieved 6.43 between D12S1663 and D12S85. Furthermore, by using haplotype analysis and gene-based mutation detection, we have identified the collagen type II, alpha 1 (COL2A1) gene, as the ANFH disease gene. Re-sequencing of the type II collagen (COL2A1) gene demonstrated a glycine with serine mutation in the G-X-Y repeat of type II collagen, in all affected individuals in three pedigrees. In the Pedigree I, a 3665G >A mutation in exon 50 of the COL2A1 gene (Genbank accession number NM_001844) and the substitution resulted in a Gly1170Ser codon change (Genbank accession number NP_001835). A second pedigree was shown to harbor the same mutation but the mutant allele existed in a different haplotype background. In a third pedigree, a 2306G>A mutation occurred in exon 33 of the gene (Genbank accession number NM_001844), causing glycine to serine change at codon 717 (Genbank accession number NP_001835).

On this basis, we propose to study the pathophysiological mechanism(s) of inherited and sporadic ANFH. The main focus of this project includes: (1) Establishing cell line and animal models to investigate the molecular basis of ANFH pathogenesis. (2) Conducting genetic analysis on sporadic ANFH cases, including those who are idiopathic, alcohol consumers or steroid-induced. (3) Using COL2A1 gene as a target, we will design novel therapeutics and prediction procedures to improve the management of the ANFH patients.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

- avascular necrosis of the femoral head

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260897

Contacts
Contact: Shih-Feng Tsai, M.D., Ph.D. (886)-37-246-166 ext 35300 petsai@nhri.org.tw

Locations
Taiwan
Division of Molecular and Genomic Medicine, National Health Research Institutes Recruiting
Miaoli County, Taiwan, 350
Contact: Shih-Feng Tsai, M.D, Ph.D    (886)-37-246-166 ext 35300      
Sponsors and Collaborators
National Health Research Institutes, Taiwan
Investigators
Principal Investigator: Wei-Ming Chen, M.D. Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00260897     History of Changes
Other Study ID Numbers: EC 9206002
Study First Received: December 1, 2005
Last Updated: May 7, 2007
Health Authority: Taiwan: Department of Health

Keywords provided by National Health Research Institutes, Taiwan:
avascular necrosis of the femoral head
genotyping
linkage analysis
pathogenesis
therapy

Additional relevant MeSH terms:
Necrosis
Osteonecrosis
Femur Head Necrosis
Pathologic Processes
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on August 28, 2014